Interview with Swee-Yeok CHU, CEO & President, EDBI/Bio One Capital
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
Address: 250 North Bridge Road,#28-00 Raffles City Tower, Singapore 179101,Singapore
Tel: +65 6832 6832
Web: http://www.edbi.com/
Bio One Capital is a leading strategic investment firm headquartered in Singapore with a worldwide presence investing to drive growth opportunities within the knowledge and innovation-intensive sectors of Biomedical Sciences, Clean Technologies, Internet & Digital Media, as well as other strategic industry clusters with commercial potential. As a value adding investor, they create sustainable and synergistic partnerships with their portfolio companies, leveraging on their broad network of resources and experience to facilitate the companies’ organic growth in Asia and the world, through their operations in Singapore
Investment firm
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
HSA celebrated its 10th anniversary in 2011. How different is the organisation today from when it started? HSA covers the regulation of health products in Singapore. However, we are quite…
In addition to being the director of strategic planning at Quintiles you are also the Chairman of BioSingapore. In this context, can you please introduce BioSingapore and describe its main…
Why did P&G decide to set up the center in Singapore? There are several reasons why P&G decided on Singapore. First, we wanted to reach more consumers, particularly in emerging…
Biomedical Research and Support Services Pte Ltd. is an NUS University spin-off that has been around for more than 14 years; last year the company name was changed to BRASS.…
In the past two years Life Technologies has been investing in Singapore— last year you opened a regional distribution center in Singapore’s Tuas Biomedical Park and this June you established…
The merger with Invitrogen-Applied Biosystems in 2008 was a big milestone for the company. As one of the leaders of this integration, can you please explain how this merger helped…
What is the presence of Boehringer Ingelheim (BI) in Southeast Asia? In 2009, Boehringer Ingelheim decided to establish a regional operating unit for its human pharmaceutical division (prescription and OTC…
Can you please give our readers a brief introduction of AB SCIEX? AB SCIEX provides scientific solutions for its customers, who are scientists that are dealing with complex chemistry, drug…
How did you start this journey of founding your company— why medical devices and why Biosensors? I have been in the medical devices industry since 1977. Therefore, for these 35…
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
Nine months ago you were appointed CEO of the company. What brought you to Dx assays? I think Dx Assays is a very interesting opportunity, which is why I came…
Why did you decide to start your own company? I started my career as a scientist with a real passion for molecular biology, and moved into pharmaceutical R&D working for…
See our Cookie Privacy Policy Here
